{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:40:07Z","timestamp":1771486807223,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2005,6,7]],"date-time":"2005-06-07T00:00:00Z","timestamp":1118102400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002In functional gastrointestinal (GI) disorders including functional dyspepsia (FD) and irritable bowel syndrome (IBS), there might be no small extent of contributions of psychosomatic factors. As a therapy for IBS patients, the effectiveness of antidepressants has been reported.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002In this study, we evaluated the efficacy of H<jats:sub>2<\/jats:sub>\u2010receptor antagonist (famotidine) and 5\u2010HT<jats:sub>4<\/jats:sub> receptor agonist (mosapride citrate). In addition, the effect of antidepressants was assessed as the second\u2010step therapy.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002Patients complaining upper GI symptoms were diagnosed as FD excluding organic diseases. Randomized patients received 20\u2003mg\/day of famotidine or 15\u2003mg\/day of mosapride citrate for 4\u2003weeks and the efficacy was compared between the two groups based on a 10\u2010point visual analogue scale. When symptoms were not relieved (score improvement 0\u20132 points), patients received amitriptyline (30\u2003mg\/day) or no medication for 4\u2003weeks randomly. Patients who had depression in psychological test (SDS) were omitted.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002As the first\u2010step therapy, both famotidine and mosapride showed beneficial effects regardless of FD subtypes, age and gender. The efficacy of these two drugs in relieving FD symptoms was not significantly different. In patients who failed in the first\u2010step therapy, amitriptyline showed beneficial effects.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002These findings might be clinically important in view of the efficient relief of symptoms in FD patients.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02473.x","type":"journal-article","created":{"date-parts":[[2005,6,19]],"date-time":"2005-06-19T15:51:18Z","timestamp":1119196278000},"page":"42-46","source":"Crossref","is-referenced-by-count":51,"title":["New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline"],"prefix":"10.1111","volume":"21","author":[{"given":"M.","family":"Otaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Odashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Oyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii37"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01303162"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70541-4"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40052.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92023-0"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529409090434"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2004.00424.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii6"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/acm.1999.5.575"},{"key":"e_1_2_5_11_2","first-page":"311","article-title":"Therapeutic strategy for the irritable bowel syndrome","volume":"16","author":"Castiglione F","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0889-8553(21)00554-9","article-title":"Treatment of the irritable bowel syndrome","volume":"20","author":"Friedman G","year":"1991","journal-title":"Gastroenterol Clin North Am"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01966.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00634443"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00160.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609006404"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00015"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00788510"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02473.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02473.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T19:43:54Z","timestamp":1695757434000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02473.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":17,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02473.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02473.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}